IONS
Ionis Pharmaceuticals Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Ionis Pharmaceuticals Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Ionis Pharmaceuticals has 14 disclosed suppliers and 10 disclosed customers in SEC filings.
Ionis Pharmaceuticals Inc
43.54
−0.85 · −1.92%
post 43.52 −0.04%
SentenceBiogen manufactures the finished drug product for SPINRAZA and QALSODY and AstraZeneca is responsible for WAINUA's commercial drug supply.
IONS 10-Kaccession 0000874015-26-000115
SentenceIn 2021, we exercised our option to license Bicycle's technology.
IONS 10-Kaccession 0000874015-26-000115
SentenceBiogen manufactures the finished drug product for SPINRAZA and QALSODY and AstraZeneca is responsible for WAINUA's commercial drug supply.
IONS 10-Kaccession 0000874015-26-000115
SentenceWe have exclusively in-licensed patents related to SPINRAZA from Cold Spring Harbor Laboratory and the University of Massachusetts.
IONS 10-Kaccession 0000874015-26-000115
SentenceFor example, we use clinical research organizations, such as Icon Clinical Research Limited, Medpace, Inc., Parexel International Corporation, Syneos Health, Inc. and Thermo Fisher Scientific Inc. for the clinical studies for our medicines, including WAINUA for the treatment of ATTR-CM, DAWNZERA, obudanersen, olezarsen, ulefnersen and zilganersen.
IONS 10-Kaccession 0000874015-26-000115
SentenceFor example, we use clinical research organizations, such as Icon Clinical Research Limited, Medpace, Inc., Parexel International Corporation, Syneos Health, Inc. and Thermo Fisher Scientific Inc. for the clinical studies for our medicines, including WAINUA for the treatment of ATTR-CM, DAWNZERA, obudanersen, olezarsen, ulefnersen and zilganersen.
IONS 10-Kaccession 0000874015-26-000115
SentenceAs a result, we paid Metagenomi to license its technologies and will pay Metagenomi certain fees for the selection of genetic targets.
IONS 10-Kaccession 0000874015-26-000115
SentenceFor example, we use clinical research organizations, such as Icon Clinical Research Limited, Medpace, Inc., Parexel International Corporation, Syneos Health, Inc. and Thermo Fisher Scientific Inc. for the clinical studies for our medicines, including WAINUA for the treatment of ATTR-CM, DAWNZERA, obudanersen, olezarsen, ulefnersen and zilganersen.
IONS 10-Kaccession 0000874015-26-000115
SentenceFor example, we use clinical research organizations, such as Icon Clinical Research Limited, Medpace, Inc., Parexel International Corporation, Syneos Health, Inc. and Thermo Fisher Scientific Inc. for the clinical studies for our medicines, including WAINUA for the treatment of ATTR-CM, DAWNZERA, obudanersen, olezarsen, ulefnersen and zilganersen.
IONS 10-Kaccession 0000874015-26-000115
SentenceFor example, we use clinical research organizations, such as Icon Clinical Research Limited, Medpace, Inc., Parexel International Corporation, Syneos Health, Inc. and Thermo Fisher Scientific Inc. for the clinical studies for our medicines, including WAINUA for the treatment of ATTR-CM, DAWNZERA, obudanersen, olezarsen, ulefnersen and zilganersen.
IONS 10-Kaccession 0000874015-26-000115
SentenceWe have exclusively in-licensed patents related to SPINRAZA from Cold Spring Harbor Laboratory and the University of Massachusetts.
IONS 10-Kaccession 0000874015-26-000115
SentenceIn December 2023, we entered into a license agreement with Vect-Horus to provide us with a worldwide, exclusive license for a specified number of targets using Vect-Horus' technology for systemic delivery of RNA-targeted therapeutics that may cross the blood-brain barrier and address targets in the central nervous system.
IONS 10-Kaccession 0000874015-26-000115
SentenceIn 2023, we entered into a royalty purchase agreement with Royalty Pharma to monetize a portion of our future SPINRAZA and pelacarsen royalties we are entitled to under our agreements with Biogen and Novartis, respectively.
SentenceUnder our collaboration agreement with Ionis, we reimbursed Ionis for identifying a development candidate and conducting an investigational new drug application, or IND, enabling toxicology study, as well as out of pocket costs incurred by Ionis related to research activities.
SentenceThe remainder of our revenue came from programs under our R&D collaborations, including a $280 million upfront payment for the global license of sapablursen to Ono in the second quarter of 2025, reflecting the value that our pipeline and technology continues to generate.
IONS 10-Kaccession 0000874015-26-000115
SentenceFor DAWNZERA's commercial drug supply, we are using CMOs to produce API and finished goods for ourselves and Otsuka.
IONS 10-Kaccession 0000874015-26-000115
SentenceFor example, in the past we have manufactured clinical trial material for AstraZeneca, Biogen, GSK, Roche, and Novartis and commercial drug supply for Biogen.
IONS 10-Kaccession 0000874015-26-000115
SentenceUnder our agreements, we are responsible for supplying finished goods inventory to Sobi and Sobi is responsible for selling each medicine to the end customer.
IONS 10-Kaccession 0000874015-26-000115
Linked news
Expected move
Inputsstraddle ±9.2%
spot 43.52exp Nov 20ATM strike 42.5ATM straddle 4.70IV 56%